COVID-19NCT05168800
CONFIDENT: Supporting Long-term Care Workers During COVID-19
A study testing Dialogue-Based Webinar, Social Media Website and Enhanced Usual Practice in people with COVID-19, run by Dartmouth-Hitchcock Medical Center at 1 site in United States.
Trial summary
The CONFIDENT Study is an online three-arm randomized trial that aims to help long-term care workers in the United States feel more confident about the Coronavirus Disease 2019 (COVID-19) vaccines. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID-19
- What is being tested?
- Dialogue-Based Webinar, Social Media Website and Enhanced Usual Practice
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,634 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Feb 2022to 20 Sep 2023
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- at least 18 years of age
- can read, write, and understand English
- lives in the United States
- has worked in a long-term care setting in the past two years
- can provide information to confirm they have worked in a long-term care setting
- is not pregnant or breastfeeding
- at least somewhat worried about the COVID-19 vaccines and/or has not received a COVID-19 vaccine booster shot
Who cannot join
- under 18 years of age
- cannot read, write, and understand English
- does not live in the United States
- has not worked in a long-term care setting in the past two years
- cannot provide information to confirm they have worked in a long-term care setting
- is pregnant or breastfeeding
- less than somewhat worried about the COVID-19 vaccines and has received at least one COVID-19 vaccine booster shot
Trial locations and contacts
1 site in 1 country.
About this study
Official title: CONFIDENT: A Randomized Trial to Increase COVID-19 Vaccine Confidence in Long-term Care Workers
The CONFIDENT Study is an online three-arm randomized trial that aims to help long-term care workers in the United States feel more confident about the Coronavirus Disease 2019 (COVID-19) vaccines. The study will compare two different interventions to usual online information (website of the Centers for Disease Control and Prevention). The first intervention is a Dialogue-Based Webinar where people can interact and ask questions about the vaccines. The second intervention is a Social Media Website that will feature curated content about the vaccines from popular social media platforms.
Participants will be asked to completed four online surveys. The first survey will be completed pre-intervention and immediately upon study enrollment (Time 0). Participants will be randomized to a trial arm at the end of the Time 0 survey. Intervention follow-up surveys will be completed 3 weeks post-randomization (Time 1), three months post-randomization (Time 2), and 6 months post-randomization (Time 3).
- Conditions
- COVID-19
- Being tested
- Dialogue-Based Webinar, Social Media Website, Enhanced Usual Practice
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dialogue-Based WebinarBehavioural
Also called Discussion Session
One-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats.
Social Media WebsiteBehavioural
Also called Social Site
A curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content.
Enhanced Usual PracticeOther
Also called Online Information
COVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website.
| Study group | Role | What they receive |
|---|---|---|
| Dialogue-Based Webinar | Experimental | Not described Receives: Behavioral: Dialogue-Based Webinar |
| Social Media Website | Experimental | Not described Receives: Behavioral: Social Media Website |
| Enhanced Usual Practice | Active comparator | Not described Receives: Other: Enhanced Usual Practice |
What is being measured
The primary outcome is the main question the study is designed to answer.
COVID-19 Vaccine Confidence
Confidence in the COVID-19 vaccines, assessed using the 3-item Vaccine Confidence Index (Larson et al., 2016) adapted for COVID-19. Each item is rated on a 5-point scale ranging from 1 ('Strongly disagree') to 5 ('Strongly agree'). Respondents are considered 'confident' (score of '1') if they respond 'Agree' or 'Strongly agree' on all three items and 'not confident' (score of '0') if one or more item responses is not 'Agree' or 'Strongly agree'.
Measured: 3 weeks post-randomization (Time 1)
Secondary outcomes (16)
Change From Baseline to 3 Weeks Post-randomization in COVID-19 Vaccine Confidence
Change in confidence in the COVID-19 vaccines from baseline to 3 weeks post-randomization, assessed using the 3-item Vaccine Confidence Index (Larson et al., 2016) adapted for COVID-19. Each item is rated on a 5-point scale ranging from 1 ('Strongly disagree') to 5 ('Strongly agree'). Respondents are considered 'confident' (score of '1') if they respond 'Agree' or 'Strongly agree' on all three items and 'not confident' (score of '0') if one or more item responses is not 'Agree' or 'Strongly agree'. For the change from baseline to Time 1 outcome, a score of 1 represents an increase in vaccine confidence (Vaccine Confidence Index score change from 0 to 1) and a score of 0 represents no change or a decrease in confidence.
Measured: Baseline (Time 0); 3 weeks post-randomization (Time 1)
Change From Baseline to 3 Months Post-randomization in COVID-19 Vaccine Confidence
Change in confidence in the COVID-19 vaccines from baseline to 3 months post-randomization, assessed using the 3-item Vaccine Confidence Index (Larson et al., 2016) adapted for COVID-19. Each item is rated on a 5-point scale ranging from 1 ('Strongly disagree') to 5 ('Strongly agree'). Respondents are considered 'confident' (score of '1') if they respond 'Agree' or 'Strongly agree' on all three items and 'not confident' (score of '0') if one or more item responses is not 'Agree' or 'Strongly agree'. For the change from baseline to Time 2 outcome, a score of 1 represents an increase in vaccine confidence (Vaccine Confidence Index score change from 0 to 1) and a score of 0 represents no change or a decrease in confidence.
Measured: Baseline (Time 0); 3 months post-randomization (Time 2)
Change From Baseline to 6 Months Post-randomization in COVID-19 Vaccine Confidence
Change in confidence in the COVID-19 vaccines from baseline to 6 months post-randomization, assessed using the 3-item Vaccine Confidence Index (Larson et al., 2016) adapted for COVID-19. Each item is rated on a 5-point scale ranging from 1 ('Strongly disagree') to 5 ('Strongly agree'). Respondents are considered 'confident' (score of '1') if they respond 'Agree' or 'Strongly agree' on all three items and 'not confident' (score of '0') if one or more item responses is not 'Agree' or 'Strongly agree'. For the change from baseline to Time 3 outcome, a score of 1 represents an increase in vaccine confidence (Vaccine Confidence Index score change from 0 to 1) and a score of 0 represents no change or a decrease in confidence.
Measured: Baseline (Time 0); 6 months post-randomization (Time 3)
Net Promoter Score (COVID-19 Vaccination)
Likelihood of recommending COVID-19 vaccination to someone who is not vaccinated, assessed using a single-item adapted Net Promoter Score item. The item is assessed on an 11-point scale ranging from 0 ('No at all likely') to 10 ('Extremely likely'). Responses are categorized into three groups: Promoters (scale score of 9 or 10) receive a score of '1', passives (scale score of 7 or 8) receive a score of '0', and detractors (scale score of 0-6) receive a score of '-1'.
Measured: 3 weeks post-randomization (Time 1)
Net Promoter Score (COVID-19 Booster Vaccination to Coworker)
Likelihood of recommending COVID-19 booster vaccination to a coworker, assessed using a single-item adapted Net Promoter Score item. The item is assessed on an 11-point scale ranging from 0 ('No at all likely') to 10 ('Extremely likely'). Responses are categorized into three groups: Promoters (scale score of 9 or 10) receive a score of '1', passives (scale score of 7 or 8) receive a score of '0', and detractors (scale score of 0-6) receive a score of '-1'.
Measured: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Uptake (Any Dose)
Receipt of any does of a COVID-19 vaccine, assessed using a single item with multiple choice (single answer) format.
Measured: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Uptake (Initial Series Completion)
Completion of initial COVID-19 vaccine series, assessed using two items with multiple choice (single answer) formats.
Measured: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Uptake (Booster Completion)
Receipt of a COVID-19 booster vaccine if initial series completed, assessed using a single item with multiple choice (single answer) format.
Measured: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Intent (Initial Series)
Intent to get a COVID-19 vaccine if unvaccinated, assessed using a single item with multiple choice (single answer) format. Response options are Yes (score of '1'), Not Sure (score of '0'), and No (score of '-1').
Measured: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Intent (Booster)
Intent to get a COVID-19 booster vaccine if not yet received, assessed using a single item with multiple choice (single answer) format. Response options are Yes (score of '1'), Not Sure (score of '0'), and No (score of '-1').
Measured: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Intent (Future Vaccine Recommendations)
Intent to get COVID-19 vaccines regularly in the future if they are recommended, assessed using a single item with multiple choice (single answer) format. Response options are Yes (score of '1'), Not Sure (score of '0'), and No (score of '-1').
Measured: 3 weeks post-randomization (Time 1)
Feeling Informed About the COVID-19 Vaccines
Extent of feeling informed (having enough information and understanding that information) about the COVID-19 vaccines, using two self-developed items. Each item is assessed on a 5-point scale ranging from 0 ('No at all confident') to 4 ('Very confident'). A single overall score is calculated as the mean of the two items (possible range 0-4).
Measured: 3 weeks post-randomization (Time 1)
Identification of COVID-19 Vaccine Information and Misinformation
Identification of COVID-19 vaccine information and misinformation, assessed using four items. Some items self-developed and some adapted from Hamel et al., 2021. Each item is assessed using a multiple choice (single answer) format. Each item response is scored as correct (value of '1') or incorrect (value of '0'). A single overall score is calculated as the sum of all four items (possible range 0-4).
Measured: 3 weeks post-randomization (Time 1)
Trust in COVID-19 Vaccine Information From Different Sources
Trust in COVID-19 vaccine information given by different people and organizations, assessed using a list of three different sources. Each source is assessed using a 4-point scale ranging from 0 ('Not at all') to 3 ('A lot'). A single overall score is calculated as the mean of the three items (possible range 0-3).
Measured: 3 weeks post-randomization (Time 1)
Change From Baseline in Secondary Outcomes
Change in secondary outcomes from baseline, assessed using the same measures identified in Outcomes 3-13.
Measured: Baseline (Time 0); 3 weeks post-randomization (Time 1); 3 months post-randomization (Time 2); 6 months post-randomization (Time 3)
As-treated Analyses of Primary and Secondary Outcomes
All primary and secondary outcomes assessed only for those who were exposed to their relevant study intervention and/or refresher intervention.
Measured: Baseline (Time 0); 3 weeks post-randomization (Time 1); 3 months post-randomization (Time 2); 6 months post-randomization (Time 3)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Dec 2021
- Study start21 Feb 2022
- Primary completion20 Feb 2023
- Study completion20 Sep 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 2,634 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Association of Health Care Assistants, Institute for Healthcare Improvement, East Carolina University, Patient-Centered Outcomes Research Institute
- Responsible party
- Principal investigator, Glyn Jones-Elwyn, Dartmouth-Hitchcock Medical Center
- Investigators
- Glyn Elwyn, Principal investigator, Dartmouth College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05168800
- Sponsor's protocol ID
- STUDY00032340
- Status last verified
- Jul 2025
- First submitted
- 21 Dec 2021
- Last updated
- 5 Aug 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: A de-identified copy of participant-level data and essential analytic code will be made available to others for research purposes, via data sharing.
Publications
Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, Cook AR, Jones NS. The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine. 2016 Oct;12:295-301. doi: 10.1016/j.ebiom.2016.08.042. Epub 2016 Sep 13.
PubMed 27658738Hamel L, Lopes L, Kirzinger A, Sparks G, Stokes M, Brodie M. KFF COVID-19 Vaccine Monitor: Media and Misinformation. 2021 Nov. Available at: https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-media-and-misinformation/
Stevens G, Johnson LC, Saunders CH, Schmidt P, Sierpe A, Thomeer RP, Little NR, Cantrell M, Yen RW, Pogue JA, Holahan T, Schubbe DC, Forcino RC, Fillbrook B, Sheppard R, Wooten C, Goldmann D, O'Malley AJ, Dube E, Durand MA, Elwyn G. The CONFIDENT study protocol: a randomized controlled trial comparing two methods to increase long-term care worker confidence in the COVID-19 vaccines. BMC Public Health. 2023 Feb 23;23(1):384. doi: 10.1186/s12889-023-15266-x.
PubMed 36823559
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CONFIDENT: A Randomized Trial to Increase COVID-19 Vaccine Confidence in Long-term Care Workers
- ClinicalTrials.gov ID
- NCT05168800
- Acronym / sponsor ID
- STUDY00032340
- Conditions
- COVID-19
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 2,634 participants (actual)
- Lead sponsor
- Dartmouth-Hitchcock Medical CenterUniversity, hospital or other
- Collaborators
- National Association of Health Care Assistants, Institute for Healthcare Improvement, East Carolina University, Patient-Centered Outcomes Research Institute
- Study start
- 21 Feb 2022 (actual)
- Primary completion
- 20 Feb 2023 (actual)
- Study completion
- 20 Sep 2023 (actual)
- First posted
- 23 Dec 2021 (actual)
- Results
- Posted 5 Aug 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The CONFIDENT Study is an online three-arm randomized trial that aims to help long-term care workers in the United States feel more confident about the Coronavirus Disease 2019 (COVID-19) vaccines. The study will compare two different interventions to usual online information (website of the Centers for Disease Control and Prevention). The first intervention is a Dialogue-Based Webinar where people can interact and ask questions about the vaccines. The second intervention is a Social Media Website that will feature curated content about the vaccines from popular social media platforms.
Participants will be asked to completed four online surveys. The first survey will be completed pre-intervention and immediately upon study enrollment (Time 0). Participants will be randomized to a trial arm at the end of the Time 0 survey. Intervention follow-up surveys will be completed 3 weeks post-randomization (Time 1), three months post-randomization (Time 2), and 6 months post-randomization (Time 3).
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Dialogue-Based Webinar | Experimental | Behavioral: Dialogue-Based Webinar |
| Social Media Website | Experimental | Behavioral: Social Media Website |
| Enhanced Usual Practice | Active comparator | Other: Enhanced Usual Practice |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- at least 18 years of age
- can read, write, and understand English
- lives in the United States
- has worked in a long-term care setting in the past two years
- can provide information to confirm they have worked in a long-term care setting
Key exclusion criteria (7 listed)
- under 18 years of age
- cannot read, write, and understand English
- does not live in the United States
- has not worked in a long-term care setting in the past two years
- cannot provide information to confirm they have worked in a long-term care setting
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dialogue-Based WebinarAlso: Discussion SessionOne-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats. | Behavioural | Dialogue-Based Webinar |
| Social Media WebsiteAlso: Social SiteA curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content. | Behavioural | Social Media Website |
| Enhanced Usual PracticeAlso: Online InformationCOVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website. | Other | Enhanced Usual Practice |
Primary outcome
COVID-19 Vaccine Confidence
Time frame: 3 weeks post-randomization (Time 1)
Confidence in the COVID-19 vaccines, assessed using the 3-item Vaccine Confidence Index (Larson et al., 2016) adapted for COVID-19. Each item is rated on a 5-point scale ranging from 1 ('Strongly disagree') to 5 ('Strongly agree'). Respondents are considered 'confident' (score of '1') if they respond 'Agree' or 'Strongly agree' on all three items and 'not confident' (score of '0') if one or more item responses is not 'Agree' or 'Strongly agree'.
16 secondary outcomes
Change From Baseline to 3 Weeks Post-randomization in COVID-19 Vaccine Confidence
Time frame: Baseline (Time 0); 3 weeks post-randomization (Time 1)
Change From Baseline to 3 Months Post-randomization in COVID-19 Vaccine Confidence
Time frame: Baseline (Time 0); 3 months post-randomization (Time 2)
Change From Baseline to 6 Months Post-randomization in COVID-19 Vaccine Confidence
Time frame: Baseline (Time 0); 6 months post-randomization (Time 3)
Net Promoter Score (COVID-19 Vaccination)
Time frame: 3 weeks post-randomization (Time 1)
Net Promoter Score (COVID-19 Booster Vaccination to Coworker)
Time frame: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Uptake (Any Dose)
Time frame: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Uptake (Initial Series Completion)
Time frame: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Uptake (Booster Completion)
Time frame: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Intent (Initial Series)
Time frame: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Intent (Booster)
Time frame: 3 weeks post-randomization (Time 1)
COVID-19 Vaccine Intent (Future Vaccine Recommendations)
Time frame: 3 weeks post-randomization (Time 1)
Feeling Informed About the COVID-19 Vaccines
Time frame: 3 weeks post-randomization (Time 1)
Identification of COVID-19 Vaccine Information and Misinformation
Time frame: 3 weeks post-randomization (Time 1)
Trust in COVID-19 Vaccine Information From Different Sources
Time frame: 3 weeks post-randomization (Time 1)
Change From Baseline in Secondary Outcomes
Time frame: Baseline (Time 0); 3 weeks post-randomization (Time 1); 3 months post-randomization (Time 2); 6 months post-randomization (Time 3)
As-treated Analyses of Primary and Secondary Outcomes
Time frame: Baseline (Time 0); 3 weeks post-randomization (Time 1); 3 months post-randomization (Time 2); 6 months post-randomization (Time 3)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 27658738Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, Cook AR, Jones NS. The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine. 2016 Oct;12:295-301. doi: 10.1016/j.ebiom.2016.08.042. Epub 2016 Sep 13.
- BackgroundHamel L, Lopes L, Kirzinger A, Sparks G, Stokes M, Brodie M. KFF COVID-19 Vaccine Monitor: Media and Misinformation. 2021 Nov. Available at: https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-media-and-misinformation/
- Derived from this study: PubMed 36823559Stevens G, Johnson LC, Saunders CH, Schmidt P, Sierpe A, Thomeer RP, Little NR, Cantrell M, Yen RW, Pogue JA, Holahan T, Schubbe DC, Forcino RC, Fillbrook B, Sheppard R, Wooten C, Goldmann D, O'Malley AJ, Dube E, Durand MA, Elwyn G. The CONFIDENT study protocol: a randomized controlled trial comparing two methods to increase long-term care worker confidence in the COVID-19 vaccines. BMC Public Health. 2023 Feb 23;23(1):384. doi: 10.1186/s12889-023-15266-x.
- Individual participant dataSharing planned: Yes. A de-identified copy of participant-level data and essential analytic code will be made available to others for research purposes, via data sharing.
Related trials for COVID-19
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
RecruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruitingObservational study
Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Glyn Elwyn principal investigator
Dartmouth College
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dialogue-Based Webinar, Social Media Website and Enhanced Usual Practice in people with COVID-19, run by Dartmouth-Hitchcock Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Aug 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
COVID-19 Vaccine Confidence (time frame: 3 weeks post-randomization (Time 1)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05168800, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2025.